<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: factors which could", fill: "#446ccf"},
{source: "1: factors which could", target: "1: differ from", fill: "#446ccf"},
{source: "1: differ from", target: "1: expectations", fill: "#446ccf"},
{source: "1: expectations", target: "1: which could negatively impact", fill: "#446ccf"},
{source: "1: which could negatively impact", target: "1: financial condition", fill: "#446ccf"},
{source: "1: financial condition", target: "1: operations", fill: "#446ccf"},
{source: "1: factors which could", target: "5: success depends on", fill: "#f88379"},
{source: "5: success depends on", target: "5: effectively", fill: "#f88379"},
{source: "5: effectively", target: "5: products against", fill: "#f88379"},
{source: "5: products against", target: "5: competitors", fill: "#f88379"},
{source: "5: success depends on", target: "8: remain competitive", fill: "#29ab87"},
{source: "8: remain competitive", target: "8: must continue", fill: "#29ab87"},
{source: "8: must continue", target: "8: new products", fill: "#29ab87"},
{source: "8: new products", target: "8: technologies", fill: "#29ab87"},
{source: "8: remain competitive", target: "20: United States ", fill: "#bc987e"},
{source: "20: United States ", target: "20: competition", fill: "#bc987e"},
{source: "20: competition", target: "20: distribution", fill: "#bc987e"},
{source: "20: distribution", target: "20: regulatory", fill: "#bc987e"},
{source: "20: regulatory", target: "20: environments", fill: "#bc987e"},
{source: "20: environments", target: "20: philosophies", fill: "#bc987e"},
{source: "20: philosophies", target: "20: preferences", fill: "#bc987e"},
{source: "20: United States ", target: "37: Group ", fill: "#6b8e23"},
{source: "37: Group ", target: "37: manufacturers", fill: "#6b8e23"},
{source: "37: manufacturers", target: "37: distributors", fill: "#6b8e23"},
{source: "37: distributors", target: "37: negotiated prices", fill: "#6b8e23"},
{source: "37: negotiated prices", target: "37: purchasing organizations affiliated hospitals", fill: "#6b8e23"},
{source: "37: Group ", target: "47: medical devices", fill: "#d6cadd"},
{source: "47: medical devices", target: "47: manufacture", fill: "#d6cadd"},
{source: "47: manufacture", target: "47: rigorous regulation by", fill: "#d6cadd"},
{source: "47: rigorous regulation by", target: "47: other Federal ", fill: "#d6cadd"},
{source: "47: other Federal ", target: "47: foreign governmental authorities", fill: "#d6cadd"},
{source: "47: medical devices", target: "98: will continue", fill: "#997a8d"},
{source: "98: will continue", target: "98: potential costs", fill: "#997a8d"},
{source: "98: potential costs", target: "98: foreign medical reimbursement policies", fill: "#997a8d"},
{source: "98: foreign medical reimbursement policies", target: "98: foreign regulatory requirements", fill: "#997a8d"},
{source: "98: foreign regulatory requirements", target: "98: differing local product preferences", fill: "#997a8d"},
{source: "98: differing local product preferences", target: "98: product requirements", fill: "#997a8d"},
{source: "98: product requirements", target: "98: fluctuations", fill: "#997a8d"},
{source: "98: fluctuations", target: "98: foreign currency exchange rates", fill: "#997a8d"},
{source: "98: foreign currency exchange rates", target: "98: diminished protection", fill: "#997a8d"},
{source: "98: diminished protection", target: "98: intellectual property", fill: "#997a8d"},
{source: "98: intellectual property", target: "98: countries outside", fill: "#997a8d"},
{source: "98: countries outside", target: "98: United States ", fill: "#997a8d"},
{source: "98: United States ", target: "98: trade protection measures", fill: "#997a8d"},
{source: "98: trade protection measures", target: "98: export licensing requirements", fill: "#997a8d"},
{source: "98: export licensing requirements", target: "98: difficulty", fill: "#997a8d"},
{source: "98: difficulty", target: "98: managing foreign operations", fill: "#997a8d"},
{source: "98: managing foreign operations", target: "98: labor force instability", fill: "#997a8d"},
{source: "98: labor force instability", target: "98: differing labor regulations", fill: "#997a8d"},
{source: "98: differing labor regulations", target: "98: potentially negative consequences from", fill: "#997a8d"},
{source: "98: potentially negative consequences from", target: "98: economic instability", fill: "#997a8d"},
{source: "98: will continue", target: "START_HERE", fill: "#997a8d"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Commercial and Professional Services</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_RTO_districts_in_Kerala">List of RTO districts in Kerala</a></td>
      <td>\n== Regional Transport Offices ==\n\n\n== Sub Regional Transport Offices ==\n\n\n== Future Sub Regional Transport Offices ==\nGovernment of Kerala has repeatedly intimated multiple legislative members that there are no plans to setup any new RTOs/SRTOs in Kerala unless the financial condition of Kerala improves.\n\n\n== References ==\n\nOfficial list of Regional Transport Offices\nOfficial list of Sub Regional Transport Offices\n\n\n== External links ==\nhttps://www.mvd.kerala.gov.in (Link to Kerala Motor Vehicles Department.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Dancing_with_the_Stars_(American_TV_series)_competitors">List of Dancing with the Stars (American TV series) competitors</a></td>
      <td>Dancing with the Stars is an American reality television show in which celebrity contestants and professional dance partners compete to be the best dancers, as determined by the show's judges and public voting. The series first broadcast in 2005, and thirty complete seasons have aired on ABC. During each season, competitors are progressively eliminated on the basis of public voting and scores received from the judges until only a few contestants remain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_product_development">New product development</a></td>
      <td>In business and engineering, new product development (NPD) covers the complete process of bringing a new product to market, renewing an existing product or introducing a product in a new market. A central aspect of NPD is product design, along with various business considerations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_design">Product design</a></td>
      <td>Product design as a verb is to create a new product to be sold by a business to its customers. A very broad coefficient and effective generation and development of ideas through a process that leads to new products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gross_domestic_product">Gross domestic product</a></td>
      <td>Gross domestic product (GDP) is a monetary measure of the market value of all the final goods and services produced in a specific time period by countries. GDP (nominal) per capita does not, however, reflect differences in the cost of living and the inflation rates of the countries; therefore, using a basis of GDP per capita at purchasing power parity (PPP) may be more useful when comparing living standards between nations, while nominal GDP is more useful comparing national economies on the international market.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Diversification_(marketing_strategy)">Diversification (marketing strategy)</a></td>
      <td>Diversification is a corporate strategy to enter into a new products or product lines, new services or new markets, involving substantially different skills, technology and knowledge.\nDiversification is one of the four main growth strategies defined by Igor Ansoff in the Ansoff Matrix:\nAnsoff pointed out that a diversification strategy stands apart from the other three strategies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_states_and_territories_of_the_United_States">List of states and territories of the United States</a></td>
      <td>The United States of America is a federal republic consisting of 50 states, a federal district (Washington, D.C., the capital city of the United States), five major territories, and various minor islands. The 48 contiguous states and Washington, D.C., are in North America between Canada and Mexico.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Republican_Party_(United_States)">Republican Party (United States)</a></td>
      <td>The Republican Party, also referred to as the GOP ("Grand Old Party"), is one of the two major contemporary political parties in the United States, along with its main historic rival, the Democratic Party.\nThe GOP was founded in 1854 by anti-slavery activists who opposed the Kansas–Nebraska Act, which allowed for the potential expansion of chattel slavery into the western territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Marine_Corps">United States Marine Corps</a></td>
      <td>The United States Marine Corps (USMC), also referred to as the United States Marines, is the maritime land force service branch of the United States Armed Forces responsible for conducting expeditionary and amphibious operations through combined arms, implementing its own infantry, artillery, aerial, and special operations forces. The U.S. Marine Corps is one of the eight uniformed services of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property">Intellectual property</a></td>
      <td>Intellectual property (IP) is a category of property that includes intangible creations of the human intellect. There are many types of intellectual property, and some countries recognize more than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property_infringement">Intellectual property infringement</a></td>
      <td>An intellectual property (IP) infringement is the infringement or violation of an intellectual property right. There are several types of intellectual property rights, such as copyrights, patents, trademarks, industrial designs, and trade secrets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/TRIPS_Agreement">TRIPS Agreement</a></td>
      <td>The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international legal agreement between all the member nations of the World Trade Organization (WTO). It establishes minimum standards for the regulation by national governments of different forms of intellectual property (IP) as applied to nationals of other WTO member nations.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ZIMMER HOLDINGS INC                              ITEM 1A Risk Factors               Risk <font color="blue">factors <font color="blue">which could</font></font> cause actual results to <font color="blue">differ from</font> our     <font color="blue">expectations</font> and <font color="blue"><font color="blue">which could</font> negatively impact</font> our <font color="blue">financial condition</font> and     results of <font color="blue">operations</font> are discussed below and elsewhere in this report</td>
    </tr>
    <tr>
      <td>The     risks and <font color="blue"><font color="blue">uncertainties</font> described</font> below are not the only ones we face</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and <font color="blue">uncertainties</font> not <font color="blue">presently known</font> to us or that are     currently not believed to be <font color="blue">significant</font> to our business <font color="blue">may also affect</font> our     actual results and <font color="blue">could harm</font> our business, <font color="blue">financial condition</font> and results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If any of the risks or <font color="blue"><font color="blue">uncertainties</font> described</font> below or any     <font color="blue"><font color="blue">additional</font> risks</font> and <font color="blue">uncertainties</font> actually occur, our business, results of     <font color="blue">operations</font>  and  <font color="blue">financial condition</font> could be <font color="blue">materially</font> and <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>RISKS RELATED TO OUR INDUSTRY              Our <font color="blue">success depends on</font> our ability to <font color="blue">effectively</font> develop and market     our <font color="blue">products against</font> those of our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>We operate in a <font color="blue">highly competitive environment</font></td>
    </tr>
    <tr>
      <td>Our present or future     products  could  be rendered obsolete or <font color="blue">uneconomical by technological</font>     <font color="blue">advances by one</font> or more of our present or future <font color="blue">competitors</font> or by other     therapies, including <font color="blue">orthobiological therapies</font></td>
    </tr>
    <tr>
      <td>To <font color="blue">remain competitive</font>, we     <font color="blue">must continue</font> to develop and acquire <font color="blue">new products</font> and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>In the global markets for <font color="blue">reconstructive</font> orthopaedic implants, trauma     products and other <font color="blue">orthopaedic products</font>, a limited number of <font color="blue">competitors</font>,     including DePuy Orthopaedics, Inc</td>
    </tr>
    <tr>
      <td>and Smith &amp; Nephew plc, compete with us for the majority of <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>(a subsidiary of Medtronic, Inc</td>
    </tr>
    <tr>
      <td>), <font color="blue">DePuy Spine </font>(a     subsidiary of Johnson &amp; Johnson), Synthes, Inc, Stryker Corporation and     EBI, LP (a subsidiary of Biomet, Inc</td>
    </tr>
    <tr>
      <td>In the dental <font color="blue">reconstructive</font>     implant  category, we compete primarily with Nobel Biocare Holding AG,     Straumann Holding AG, and Implant Innovations, Inc</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>is <font color="blue">primarily on</font> the basis of:       •  <font color="blue">technology</font>;     •  innovation;     •  quality;     •  reputation;     •  <font color="blue"><font color="blue">relationships</font> with customers</font>; and     •  service</td>
    </tr>
    <tr>
      <td>In local markets outside of the <font color="blue">United States</font>, other factors influence     <font color="blue">competition</font> as well, including:       •  local <font color="blue">distribution</font> systems;     •  complex <font color="blue">regulatory</font> <font color="blue">environments</font>; and     •  differing medical <font color="blue">philosophies</font> and product <font color="blue">preferences</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may:       •  have greater financial, marketing and other <font color="blue">resources than us</font>;     •  respond more quickly to new or emerging <font color="blue">technologies</font>;     •  undertake more extensive <font color="blue">marketing campaigns</font>;     •  adopt more <font color="blue">aggressive pricing policies</font>; or     •  be more successful in attracting <font color="blue">potential customers</font>, employees and     <font color="blue">strategic partners</font></td>
    </tr>
    <tr>
      <td>Any of these factors, alone or in <font color="blue">combination</font>, could cause us to have     <font color="blue">difficulty</font> maintaining or <font color="blue">increasing sales</font> of our products</td>
    </tr>
    <tr>
      <td>If third-party payors decline to reimburse our customers for our     products or <font color="blue">reduce <font color="blue">reimbursement</font> levels</font>, the demand for our <font color="blue">products may</font>     decline and our ability to sell our <font color="blue">products profitably may</font> be harmed</td>
    </tr>
    <tr>
      <td>We sell our products and services to hospitals, doctors, dentists and     other <font color="blue">health care providers</font>, all of which receive <font color="blue">reimbursement</font> for the     <font color="blue">health care services provided</font> to their patients from third-party payors,     <font color="blue">such as domestic</font> and international <font color="blue">government</font> programs, private insurance     plans  and  managed  care  programs</td>
    </tr>
    <tr>
      <td>These third-party payors may deny     <font color="blue">reimbursement</font> if they determine that a device used in a procedure was not in     accordance with cost-effective treatment methods, as determined by the     third-party payor, or was used for an <font color="blue">unapproved indication</font></td>
    </tr>
    <tr>
      <td>Third-party     payors  may  <font color="blue">also decline</font> to reimburse for <font color="blue">experimental procedures</font> and     devices</td>
    </tr>
    <tr>
      <td>If our products are not considered cost-effective by third-party     payors, our <font color="blue">customers may</font> not be reimbursed for our products</td>
    </tr>
    <tr>
      <td>In addition, third-party payors are <font color="blue">increasingly attempting</font> to contain     <font color="blue">health care costs by limiting both coverage</font> and the level of <font color="blue">reimbursement</font>     for <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td>For example, <font color="blue">managed care</font> programs often     <font color="blue">prescribe only</font> those <font color="blue">orthopaedic recovery products</font> that match a <font color="blue">patient as</font>     to age, need for mobility and other <font color="blue">parameters</font> in an effort to provide more     cost-effective care</td>
    </tr>
    <tr>
      <td>If third-party payors <font color="blue">reduce <font color="blue">reimbursement</font> levels</font> to     hospitals and other <font color="blue">health care providers</font> for our products, demand for our     <font color="blue">products may</font> decline or we may experience pressure to reduce the prices of     our products, <font color="blue">which could</font> have a material adverse effect on sales, financial     condition and results of operation</td>
    </tr>
    <tr>
      <td>In international markets, where the <font color="blue">movement toward health care reform</font>     and the <font color="blue">development</font> of <font color="blue">managed care</font> are <font color="blue">generally</font> not <font color="blue">as advanced as</font> in the     <font color="blue">United States</font>, we have experienced <font color="blue">downward pressure on product pricing</font> and     other  effects  of  health  care  reform</td>
    </tr>
    <tr>
      <td>In  Japan,  for  example, a     <font color="blue">government</font>-operated insurance system <font color="blue">reimburses</font> customers                                                                           15       _________________________________________________________________    [69]Table of Contents       ZIMMER HOLDINGS, INC AND SUBSIDIARIES 2005 FORM 10-K         for our products</td>
    </tr>
    <tr>
      <td>Under this system, the Japanese <font color="blue"><font color="blue">government</font> periodically</font>     reviews and reduces the <font color="blue">reimbursement</font> levels for products</td>
    </tr>
    <tr>
      <td><font color="blue">If the Japanese     </font><font color="blue"><font color="blue">government</font> continues</font> to reduce the <font color="blue">reimbursement</font> level for orthopaedic     products, our sales, <font color="blue">financial condition</font> and results of <font color="blue">operation may</font> be     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>We are subject to cost-containment efforts of <font color="blue">healthcare purchasing</font>     <font color="blue">organizations</font>, which may have a material adverse effect on our financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Many existing and <font color="blue">potential customers</font> for our products have combined to     form group <font color="blue"><font color="blue">purchasing organization</font>s</font> in an effort to <font color="blue">contain costs</font></td>
    </tr>
    <tr>
      <td><font color="blue">Group     </font><font color="blue"><font color="blue">purchasing organization</font>s</font> negotiate pricing <font color="blue">arrangements</font> with medical supply     <font color="blue"><font color="blue">manufacture</font>rs</font>  and  <font color="blue">distributors</font>, and these <font color="blue">negotiated prices</font> are made     available to a group <font color="blue">purchasing organization</font>’s affiliated hospitals and     other  members</td>
    </tr>
    <tr>
      <td>If we are not one of the <font color="blue">providers selected by</font> a group     <font color="blue">purchasing organization</font>, affiliated hospitals and other members may be less     likely to purchase our products, and if the group <font color="blue">purchasing organization</font>     has negotiated a <font color="blue">strict compliance contract</font> for another <font color="blue">manufacture</font>r’s     products, we may be <font color="blue">precluded from</font> making sales to members of the group     <font color="blue">purchasing organization</font> for the duration of the <font color="blue">contractual arrangement</font></td>
    </tr>
    <tr>
      <td>Our     failure to respond to the cost-containment efforts of group purchasing     <font color="blue"><font color="blue">organizations</font> may</font> cause us to <font color="blue">lose market</font> share to our <font color="blue">competitors</font> and could     have a material adverse effect on our sales, <font color="blue">financial condition</font> and results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are involved in an ongoing <font color="blue">investigation</font> by the <font color="blue"><font color="blue">United States</font> </font>    Department of Justice of companies in the <font color="blue">orthopaedics industry</font>, the results     of  which  may  have a material adverse effect on our sales, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>On March 31, 2005, we received a <font color="blue">subpoena from</font> the <font color="blue"><font color="blue">United States</font> </font>    Department of Justice through the <font color="blue"><font color="blue">United States</font> </font>Attorney’s Office in Newark,     New  Jersey,  requesting  <font color="blue">documents</font> related to <font color="blue">consulting contracts</font> or     <font color="blue">professional</font>  <font color="blue">service <font color="blue">agreements</font></font> we have <font color="blue">with <font color="blue">orthopaedic surgeons</font></font></td>
    </tr>
    <tr>
      <td>We     understand that similar inquiries were directed to <font color="blue">at least four</font> other     companies  in the <font color="blue">orthopaedics industry</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">cooperating fully with</font>     <font color="blue">federal <font color="blue">authorities</font> with</font> regard to this matter</td>
    </tr>
    <tr>
      <td>If, as a result of this     <font color="blue">investigation</font>, we are found to have <font color="blue">violated one</font> or more <font color="blue">applicable laws</font>,     our  business,  <font color="blue">financial condition</font> and results of <font color="blue">operations</font> could be     <font color="blue">materially</font> <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>If some of our existing business practices     are <font color="blue">challenged as unlawful</font>, we may have to change those practices, which     could have a material adverse effect on our business, <font color="blue">financial condition</font>     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We and our customers are subject to various <font color="blue"><font color="blue">government</font>al</font> <font color="blue">regulations</font>     and we may incur <font color="blue">significant</font> expenses to comply with these <font color="blue">regulations</font> and     develop products compatible with these <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">medical devices</font> we design, develop, <font color="blue">manufacture</font> and market are     subject to <font color="blue">rigorous regulation by</font> the FDA and numerous other Federal, state     and foreign <font color="blue"><font color="blue">government</font>al</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>The process of obtaining <font color="blue">regulatory</font>     approvals to market a medical device, <font color="blue">particularly from</font> the FDA and certain     foreign <font color="blue"><font color="blue">government</font>al</font> <font color="blue">authorities</font>, can be costly and time consuming and     approvals might not be granted for future products on a timely basis, if at     all</td>
    </tr>
    <tr>
      <td>Delays in receipt of, or failure to obtain, approvals for future     <font color="blue">products could</font> result in <font color="blue">delayed realization</font> of <font color="blue">product revenues</font> or in     substantial <font color="blue"><font color="blue">additional</font> costs <font color="blue">which could</font></font> have a material adverse effect on     our business or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, if we fail to <font color="blue">comply with applicable</font> FDA medical device or     other material <font color="blue">regulatory</font> requirements, including, for example, the Quality     System Regulation, recordkeeping <font color="blue">regulations</font>, <font color="blue">labeling requirements</font> and     <font color="blue">adverse event</font> reporting <font color="blue">regulations</font>, that <font color="blue">failure could</font> result in, among     other things:       •  <font color="blue">warning letters</font>;     •  fines or <font color="blue">civil penalties</font>;     •  <font color="blue">injunctions</font>;     •  repairs, replacements or refunds;     •  recalls or seizures of products;     •  total or <font color="blue">partial suspension</font> of production;     •  the US Food and Drug Administration’s refusal to <font color="blue">grant future premarket</font>     <font color="blue">clearances</font> or approvals;     •  <font color="blue">withdrawals</font> or <font color="blue">suspensions</font> of <font color="blue">current product <font color="blue">applications</font></font>; and     •  <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>Any of these actions, in <font color="blue">combination</font> or alone, could have a material     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In many of the <font color="blue">foreign countries</font> in which we market our products, we     are subject to <font color="blue">regulations</font> affecting, among other things:       •  <font color="blue">clinical efficacy</font>;     •  <font color="blue">product standards</font>;     •  <font color="blue">packaging requirements</font>;     •  <font color="blue">labeling requirements</font>;     •  import/export restrictions;     •  tariff <font color="blue">regulations</font>;     •  duties; and     •  <font color="blue">tax requirements</font></td>
    </tr>
    <tr>
      <td>Many of the <font color="blue">regulations</font> applicable to our devices and products in these     countries, such as the European Medical Devices Directive, are similar to     those of the FDA In addition, in many countries the <font color="blue">national health</font> or     <font color="blue">social security <font color="blue">organizations</font></font> require our products to be qualified before     they can be <font color="blue">marketed with</font> the benefit of <font color="blue">reimbursement</font> eligibility</td>
    </tr>
    <tr>
      <td><font color="blue">Failure     </font>to receive or delays in the receipt of, <font color="blue">relevant foreign qualifications also</font>     could have a material adverse effect on our business, <font color="blue">financial condition</font>     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>As  both  the  FDA and foreign <font color="blue">government</font> <font color="blue">regulators</font> have become     increasingly stringent, we may be subject to more <font color="blue">rigorous regulation by</font>     <font color="blue"><font color="blue">government</font>al</font> <font color="blue">authorities</font> in the future</td>
    </tr>
    <tr>
      <td>Our products and <font color="blue">operations</font> are also     often subject to the rules of industrial standards bodies, such as the     <font color="blue">International Standards Organization</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">adequately address</font> any     of these <font color="blue">regulations</font>, our business will be harmed</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">health care fraud</font> and abuse <font color="blue">regulations</font> that could     require us to change our       16       _________________________________________________________________    [70]Table of Contents       ZIMMER HOLDINGS, INC AND SUBSIDIARIES 2005 FORM 10-K         business practices and restrict our <font color="blue">operations</font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Violations </font>of these laws are punishable by criminal     and/or civil sanctions, including, in some instances, fines, <font color="blue">imprisonment</font>     and, within the <font color="blue">United States</font>, <font color="blue">exclusion from participation</font> in <font color="blue">government</font>     <font color="blue">healthcare programs</font>, including Medicare, Medicaid, Veterans Administration     (VA) <font color="blue">health programs</font> and Civilian Health and Medical Program Uniformed     Service (CHAMPUS)</td>
    </tr>
    <tr>
      <td>The scope and <font color="blue">enforcement</font> of these laws and <font color="blue">regulations</font>     are uncertain and subject to rapid change</td>
    </tr>
    <tr>
      <td>Because of the far-reaching and     uncertain nature of these laws, we are required to monitor our practices to     remain in <font color="blue">compliance with</font> these laws</td>
    </tr>
    <tr>
      <td>If we were to <font color="blue">violate one</font> or more of     these laws, our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font>     could  be  <font color="blue">materially</font> <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>If there is a change in law,     regulation  or <font color="blue">administrative</font> or <font color="blue">judicial interpretations</font>, some of our     existing  business <font color="blue">practices could</font> be <font color="blue">challenged as unlawful</font> and, as a     result, we may have to change those practices, <font color="blue">which could</font> have a material     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may incur product <font color="blue">liability</font> losses</font>, and <font color="blue">insurance coverage may</font> be     inadequate or unavailable to cover these losses</td>
    </tr>
    <tr>
      <td>Our business is subject to <font color="blue">potential product <font color="blue">liability</font> risks</font> that are     inherent in the design, <font color="blue">development</font>, <font color="blue">manufacture</font> and marketing of medical     devices</td>
    </tr>
    <tr>
      <td>Our  products  are often used in surgical and <font color="blue">intensive care</font>     settings</td>
    </tr>
    <tr>
      <td>In addition, some of the <font color="blue">medical devices</font> we <font color="blue">manufacture</font> and sell     are designed to be implanted in the human body for <font color="blue">long periods</font> of time</td>
    </tr>
    <tr>
      <td>In     the ordinary course of business, we are the subject of product <font color="blue">liability</font>     lawsuits alleging that component failures, <font color="blue">manufacturing</font> flaws, design     defects or inadequate <font color="blue">disclosure</font> of product-related risks or product-related     information resulted in an <font color="blue">unsafe condition</font> or injury to patients</td>
    </tr>
    <tr>
      <td><font color="blue">Product     </font><font color="blue">liability</font> lawsuits and claims, <font color="blue">safety alerts</font> or product recalls, regardless     of their ultimate outcome, could have a material adverse effect on our     business and reputation and on our ability to attract and retain customers</td>
    </tr>
    <tr>
      <td>As part of our <font color="blue">risk <font color="blue">management</font> policy</font>, we maintain third-party product     <font color="blue">liability</font> insurance coverage</td>
    </tr>
    <tr>
      <td>However, product <font color="blue">liability</font> claims <font color="blue">against us</font>     may exceed the <font color="blue">coverage limits</font> of our <font color="blue">insurance policies</font> or cause us to     record a self-insured loss</td>
    </tr>
    <tr>
      <td>Even if any product <font color="blue">liability</font> loss is <font color="blue">covered by</font>     an <font color="blue">insurance policy</font>, these <font color="blue">policies may</font> have substantial <font color="blue">retentions</font> or     <font color="blue">deductibles</font> that provide that we will not receive <font color="blue">insurance proceeds until</font>     the <font color="blue">losses incurred exceed</font> the amount of those <font color="blue">retentions</font> or <font color="blue">deductibles</font></td>
    </tr>
    <tr>
      <td>We     will be responsible for paying any losses that are below those <font color="blue">retentions</font> or     <font color="blue">deductibles</font></td>
    </tr>
    <tr>
      <td>A product <font color="blue">liability</font> claim in excess of <font color="blue">applicable insurance</font>     could have a material adverse effect on our business, <font color="blue">financial position</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>RISKS RELATED TO OUR BUSINESS               If  we  fail  to <font color="blue">effectively</font> utilize the skills and knowledge of     <font color="blue">orthopaedic surgeons</font>, <font color="blue">customers may</font> not buy our products and our revenue and     <font color="blue"><font color="blue">profitability</font> may decline</font></td>
    </tr>
    <tr>
      <td>We maintain <font color="blue">professional</font> <font color="blue">relationships</font> with a number of orthopaedic     surgeons who assist in <font color="blue">product research</font> and <font color="blue">development</font> and <font color="blue">advise us on how</font>     to satisfy the full range of surgeon and patient needs</td>
    </tr>
    <tr>
      <td>These <font color="blue">professional</font>s     speak about our products at medical seminars, assist in the training of     other <font color="blue">professional</font>s in the use of our products and <font color="blue"><font color="blue">provide us</font> with feedback</font>     on  the  industry’s acceptance of our <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>The failure of our     products to retain the support of <font color="blue">orthopaedic surgeons</font>, who <font color="blue">frequently</font>     <font color="blue">recommend products</font> or are involved in <font color="blue">product selection decisions</font>, or the     failure  of our <font color="blue">new products</font> to secure and retain similar <font color="blue">support from</font>     surgeons, could have a material adverse effect on our business, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we fail to retain the <font color="blue"><font color="blue">independent</font> agents</font> and <font color="blue">distributors</font> upon whom     we <font color="blue">rely heavily</font> to market our products, <font color="blue">customers may</font> not buy our products     and our revenue and <font color="blue"><font color="blue">profitability</font> may decline</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">marketing success</font> in the <font color="blue"><font color="blue">United States</font> </font>and abroad depends largely     upon  our agents’ and <font color="blue">distributors</font>’ sales and service expertise in the     marketplace</td>
    </tr>
    <tr>
      <td>Many of these agents have developed <font color="blue">professional</font> <font color="blue">relationships</font>     with existing and <font color="blue">potential customers</font> because of their detailed knowledge of     products and <font color="blue">instruments</font></td>
    </tr>
    <tr>
      <td>Many <font color="blue">commonly provide</font> operating room personnel     <font color="blue">with implant</font> and instrument <font color="blue">product training as well as product support</font> in     the operating room</td>
    </tr>
    <tr>
      <td>A loss of a <font color="blue">significant</font> number of these <font color="blue">agents could</font>     have a material adverse effect on our business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If some of the business practices of our <font color="blue">independent</font>     <font color="blue">sales agents</font> and <font color="blue">distributors</font> are <font color="blue">challenged as unlawful</font>, they may have to     change those practices, <font color="blue">which could</font> have a material adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we do not introduce <font color="blue">new products</font> in a timely manner, our products     <font color="blue">may become obsolete over</font> time, <font color="blue">customers may</font> not buy our products and our     revenue and <font color="blue"><font color="blue">profitability</font> may decline</font></td>
    </tr>
    <tr>
      <td>Demand for our <font color="blue">products may</font> change, in certain cases, in ways we may     not anticipate because of:       •  evolving customer needs;       •  changing <font color="blue">demographics</font>;       •  slowing industry growth rates;       •  declines in the <font color="blue">reconstructive</font> implant market;       •  the <font color="blue">introduction</font> of <font color="blue">new products</font> and <font color="blue">technologies</font>;       •  evolving surgical <font color="blue">philosophies</font>; and       •  <font color="blue">evolving industry standards</font></td>
    </tr>
    <tr>
      <td>Without the timely <font color="blue">introduction</font> of <font color="blue">new products</font> and <font color="blue">enhancements</font>, our     <font color="blue">products may</font> become obsolete over time</td>
    </tr>
    <tr>
      <td>If that happens, our revenue and     operating results <font color="blue">would suffer</font></td>
    </tr>
    <tr>
      <td>The success of our <font color="blue">new product offerings</font>     <font color="blue">will <font color="blue">depend on</font> several factors</font>, including our ability to:       •  properly identify and anticipate customer needs;       •  <font color="blue">commercialize</font> <font color="blue">new products</font> in a timely manner;                                                                           17       _________________________________________________________________    [71]Table of Contents       ZIMMER HOLDINGS, INC AND SUBSIDIARIES 2005 FORM 10-K         •  <font color="blue">manufacture</font> and deliver <font color="blue">instruments</font> and products in <font color="blue">sufficient volumes on</font>     time;       •  <font color="blue">different</font>iate our offerings from <font color="blue">competitors</font>’ offerings;       •  achieve positive <font color="blue">clinical outcomes</font> for <font color="blue">new products</font>;       •   satisfy  the increased demands by healthcare payors, providers and     patients for shorter hospital stays, faster post-operative recovery and     lower-cost procedures;       •   innovate  and  develop new materials, product designs and surgical     <font color="blue">techniques</font>; and       •  <font color="blue">provide adequate medical education</font> relating to <font color="blue">new products</font> and attract     <font color="blue">key surgeons</font> to advocate these <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>In addition, new materials, product designs and surgical <font color="blue">techniques</font>     that we develop may not be <font color="blue">accepted quickly</font>, in some or all markets, because     of, among other factors:       •  <font color="blue">entrenched patterns</font> of <font color="blue">clinical practice</font>;       •  the need for <font color="blue">regulatory</font> clearance; and       •  <font color="blue"><font color="blue">uncertainty</font> with respect</font> to third-party <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>Moreover, innovations <font color="blue">generally</font> require a substantial <font color="blue">investment</font> in     research and <font color="blue">development</font> before we can determine their <font color="blue">commercial viability</font>     and  we  may  not  have  the <font color="blue">financial resources necessary</font> to fund the     production</td>
    </tr>
    <tr>
      <td>In  addition, even if we are able to <font color="blue">successfully</font> develop     <font color="blue">enhancements</font> or new <font color="blue">generations</font> of our products, these <font color="blue">enhancements</font> or new     <font color="blue">generations</font> of <font color="blue">products may</font> not produce revenue in excess of the costs of     <font color="blue">development</font> and they may be quickly rendered <font color="blue">obsolete by</font> changing customer     <font color="blue">preferences</font> or the <font color="blue">introduction</font> by our <font color="blue">competitors</font> of <font color="blue">products embodying new</font>     <font color="blue">technologies</font> or features</td>
    </tr>
    <tr>
      <td>We conduct a <font color="blue">significant</font> amount of our <font color="blue">sales activity outside</font> of the     <font color="blue">United States</font>, <font color="blue">which subjects us</font> to <font color="blue">additional</font> business risks and may cause     our <font color="blue">profitability</font> to <font color="blue">decline due</font> to <font color="blue">increased costs</font></td>
    </tr>
    <tr>
      <td>Because we sell our products in more than 100 countries, our business     is subject to <font color="blue">risks associated with</font> doing business <font color="blue">internationally</font></td>
    </tr>
    <tr>
      <td>In 2005,     we derived <font color="blue">approximately</font> dlra1cmam344 million, or 41prca of our total revenue, from     sales of our <font color="blue">products outside</font> of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We intend to continue to     <font color="blue">pursue growth opportunities</font> in sales <font color="blue">internationally</font>, <font color="blue">which could</font> expose us     to <font color="blue"><font color="blue">additional</font> risks</font> associated with international sales and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our     international <font color="blue">operations</font> are, and <font color="blue">will continue</font> to be, subject to a number     of risks and <font color="blue">potential costs</font>, including:       •  changes in foreign medical <font color="blue">reimbursement</font> policies and programs;       •  unexpected changes in foreign <font color="blue">regulatory</font> requirements;       •  differing local product <font color="blue">preferences</font> and <font color="blue">product requirements</font>;       •  <font color="blue">fluctuations</font> in <font color="blue">foreign currency exchange rates</font>;       •  <font color="blue">diminished protection</font> of <font color="blue"><font color="blue">intellectual</font> property</font> in some <font color="blue">countries outside</font>     of the <font color="blue">United States</font>;       •  <font color="blue">trade protection measures</font> and import or <font color="blue">export licensing requirements</font>;       •  <font color="blue">difficulty</font> in staffing and managing foreign <font color="blue">operations</font>;       •  <font color="blue">labor force instability</font>;       •  differing labor <font color="blue">regulations</font>;       •  <font color="blue">potentially negative <font color="blue">consequences</font> from</font> changes in tax laws; and       •  political and <font color="blue">economic instability</font></td>
    </tr>
    <tr>
      <td>Any of these factors may, <font color="blue">individually</font> or as a group, have a material     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  are  subject  to  risks  arising <font color="blue">from currency exchange rate</font>     <font color="blue">fluctuations</font>, which can increase our costs and may cause our <font color="blue">profitability</font>     to decline</td>
    </tr>
    <tr>
      <td>A substantial portion of our <font color="blue">foreign generated revenues</font> are generated     in <font color="blue">Europe and Japan</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">United States</font> </font><font color="blue">dollar value</font> of our foreign-generated     revenues  varies with currency exchange rate <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant     </font>increases in the value of the <font color="blue"><font color="blue">United States</font> </font><font color="blue">dollar relative</font> to the Euro or     the Japanese Yen, as well as other currencies, could have a material adverse     effect on our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">address currency risk <font color="blue">management</font></font>     through regular operating and <font color="blue">financing <font color="blue">activities</font></font>, and on a limited basis,     through  the  use  of <font color="blue">derivative</font> financial <font color="blue">instruments</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">derivative</font>     financial <font color="blue">instruments</font> we <font color="blue">enter into</font> are in the form of <font color="blue">foreign exchange</font>     <font color="blue">forward contracts with major financial institutions</font></td>
    </tr>
    <tr>
      <td>The forward contracts     are designed to hedge anticipated foreign currency transactions, primarily     <font color="blue">intercompany sale</font> and <font color="blue">purchase transactions</font>, for <font color="blue">periods consistent with</font>     <font color="blue">commitments</font></td>
    </tr>
    <tr>
      <td>Realized and unrealized gains and losses on these contracts     that  qualify  as  cash  flow hedges are <font color="blue">temporarily</font> recorded in other     comprehensive income, then recognized in earnings when the hedged item     <font color="blue">affects net earnings</font></td>
    </tr>
    <tr>
      <td>We may fail to <font color="blue">adequately protect</font> our proprietary <font color="blue">technology</font> and other     <font color="blue"><font color="blue">intellectual</font> property</font>, which would allow <font color="blue">competitors</font> or others to take     advantage of our research and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>Our  long-term  <font color="blue">success largely depends on</font> our ability to market     <font color="blue">technologically competitive products</font></td>
    </tr>
    <tr>
      <td>If we fail to obtain or maintain     adequate <font color="blue"><font color="blue">intellectual</font> property</font> protection, we may not be able to prevent     <font color="blue">third parties from using</font> our proprietary <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Also, our currently     pending or <font color="blue">future <font color="blue">patent <font color="blue">applications</font></font> may</font> not result in <font color="blue">issued patents</font></td>
    </tr>
    <tr>
      <td>In     the  <font color="blue">United States</font>, <font color="blue">patent <font color="blue">applications</font></font> are <font color="blue">confidential</font> for 18 months     following their filing, and because <font color="blue">third parties may</font> have <font color="blue">filed patent</font>     <font color="blue">applications</font> for <font color="blue">technology</font> <font color="blue">covered by</font> our pending <font color="blue">patent <font color="blue">applications</font></font>     without our being aware of those <font color="blue">applications</font>, our <font color="blue">patent <font color="blue">applications</font></font> may     not have priority over <font color="blue">patent <font color="blue">applications</font></font> of others</td>
    </tr>
    <tr>
      <td>In addition, our     <font color="blue">issued patents</font> may not contain claims <font color="blue">sufficiently broad</font> to <font color="blue">protect us</font>     <font color="blue">against third parties with</font> similar <font color="blue">technologies</font> or products, or <font color="blue">provide us</font>     with  any <font color="blue">competitive advantage</font></td>
    </tr>
    <tr>
      <td>If a third party initiates <font color="blue">litigation</font>     regarding our patents, our <font color="blue">collaborators</font>’ patents, or those patents for     which we have license rights, and is successful, a court could declare our     patents invalid or unenforceable or limit the scope of coverage of those     patents</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">United States</font> </font>Patent and Trademark Office (USPTO) and the courts     have not <font color="blue">consistently treated</font> the breadth of claims allowed or interpreted     in orthopaedic <font color="blue">reconstructive</font> implant and bio<font color="blue">technology</font> patents</td>
    </tr>
    <tr>
      <td>If the     USPTO or the <font color="blue">courts begin</font> to allow or interpret claims more       18       _________________________________________________________________    [72]Table of Contents       ZIMMER HOLDINGS, INC AND SUBSIDIARIES 2005 FORM 10-K         broadly, the incidence and cost of <font color="blue">patent interference proceedings</font> and the     risk of <font color="blue">infringement</font> <font color="blue">litigation</font> will likely increase</td>
    </tr>
    <tr>
      <td>On the other hand, if     the USPTO or the <font color="blue">courts begin</font> to allow or interpret claims more narrowly,     the value of our <font color="blue">proprietary rights may</font> be reduced</td>
    </tr>
    <tr>
      <td>Any changes in, or     <font color="blue">unexpected interpretations</font> of, the patent laws may <font color="blue">adversely</font> affect our     ability to enforce our <font color="blue">patent position</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue"><font color="blue">intellectual</font> property</font> rights may be unavailable or limited     in some <font color="blue">foreign countries</font>, <font color="blue">which could</font> make it easier for <font color="blue">competitors</font> to     <font color="blue">capture market position</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font><font color="blue">may also capture market</font> share from us     by  <font color="blue">designing products</font> that mirror the <font color="blue">capabilities</font> of our products or     <font color="blue">technology</font> without infringing our <font color="blue"><font color="blue">intellectual</font> property</font> rights</td>
    </tr>
    <tr>
      <td>If we do not     obtain <font color="blue">sufficient international protection</font> for our <font color="blue"><font color="blue">intellectual</font> property</font>,     our <font color="blue">competitiveness</font> in <font color="blue">international markets could</font> be impaired, which would     limit our growth and <font color="blue">future revenue</font></td>
    </tr>
    <tr>
      <td>We also rely upon trade secrets, proprietary know-how, and continuing     <font color="blue">technological innovation</font> to <font color="blue">remain competitive</font></td>
    </tr>
    <tr>
      <td>We attempt to protect this     information <font color="blue">with security measures</font>, including the use of <font color="blue">confidential</font>ity     <font color="blue"><font color="blue">agreements</font> with</font> our employees, consultants, and corporate <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">individuals may breach</font> these <font color="blue">agreements</font> and any <font color="blue">remedies available</font> to     us may be insufficient to compensate our damages</td>
    </tr>
    <tr>
      <td>Furthermore, our trade     secrets, know-how and other <font color="blue">technology</font> may otherwise become known or be     <font color="blue">independent</font>ly dis<font color="blue">covered by</font> our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>We may be subject to <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">litigation</font> and <font color="blue">infringement</font>     claims, <font color="blue">which could</font> cause us to incur <font color="blue">significant</font> expenses or <font color="blue">prevent us</font>     <font color="blue">from selling</font> our products</td>
    </tr>
    <tr>
      <td>A  successful  claim  of  patent  or other <font color="blue"><font color="blue">intellectual</font> property</font>     <font color="blue">infringement</font> <font color="blue">against us</font> could <font color="blue">adversely</font> affect our growth and <font color="blue">profitability</font>,     in some cases <font color="blue">materially</font></td>
    </tr>
    <tr>
      <td>From time to time, we receive notices from third     parties  of  potential  <font color="blue">infringement</font>  and  receive claims of potential     <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>We may be unaware of <font color="blue"><font color="blue">intellectual</font> property</font> rights of others     that may cover some of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>If someone claims that our products     infringed their <font color="blue"><font color="blue">intellectual</font> property</font> rights, any resulting <font color="blue">litigation</font> could     be costly and time consuming and <font color="blue">would divert</font> the attention of <font color="blue">management</font>     and  key  personnel  from other business issues</td>
    </tr>
    <tr>
      <td>The <font color="blue">complexity</font> of the     <font color="blue">technology</font> involved and the <font color="blue">uncertainty</font> of <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">litigation</font>     increase these risks</td>
    </tr>
    <tr>
      <td>Claims of <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">infringement</font> also     might  require  us to <font color="blue">enter into</font> costly royalty or license <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>However, we may be unable to obtain royalty or license <font color="blue">agreements</font> on terms     acceptable to us or at all</td>
    </tr>
    <tr>
      <td>We also may be subject to <font color="blue">significant</font> damages or     an injunction preventing us from <font color="blue">manufacturing</font>, selling or using some of our     products in the event of a successful claim of patent or other <font color="blue">intellectual</font>     property  <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>Any of these adverse <font color="blue">consequences</font> could have a     material adverse effect on our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may complete <font color="blue">additional</font> <font color="blue">acquisition</font>s, <font color="blue">which could</font> increase our costs     or <font color="blue">liabilities</font> or be <font color="blue">disruptive</font></td>
    </tr>
    <tr>
      <td>We intend to continue to look for <font color="blue">additional</font> strategic <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>We     may  not  be  able to complete <font color="blue">additional</font> <font color="blue">acquisition</font>s or to integrate     <font color="blue">successfully</font> any acquired <font color="blue">businesses without</font> substantial expense, delay or     other operational or <font color="blue">financial problems</font></td>
    </tr>
    <tr>
      <td><font color="blue">Acquiring </font>and <font color="blue">integrating</font> new     businesses involves risk, including the following:       •  we may need to divert more <font color="blue">management</font> resources to <font color="blue">integration</font> than we     planned, which may <font color="blue">adversely</font> affect our ability to pursue other more     profitable <font color="blue">activities</font>;       •  the <font color="blue">difficulties</font> of <font color="blue">integration</font> may be increased if we need to integrate     <font color="blue">geographically</font> separated <font color="blue">organizations</font>, personnel with disparate business     <font color="blue">backgrounds</font> and companies with <font color="blue">different</font> corporate cultures;     •   we  may not eliminate as many redundant costs as we anticipated in     selecting our <font color="blue">acquisition</font> <font color="blue">candidates</font>; and       •  one or more of our <font color="blue">acquisition</font> <font color="blue">candidates</font> also may have <font color="blue">liabilities</font> or     adverse operating issues that we failed to discover through our diligence     prior to the <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>If we are unable to form <font color="blue">strategic alliances</font>, or if our strategic     <font color="blue">alliances fail</font> to achieve their <font color="blue">objectives</font>, our operating results will be     <font color="blue">negatively impacted</font></td>
    </tr>
    <tr>
      <td>Several of our strategic <font color="blue">initiatives</font> involve alliances with other     orthopaedic and bio<font color="blue">technology</font> companies</td>
    </tr>
    <tr>
      <td>These include our <font color="blue">agreement with</font>     Revivicor, Inc</td>
    </tr>
    <tr>
      <td>relating to orthopaedic tissue <font color="blue">technology</font>, our <font color="blue">collaboration</font>     with ISTO Technologies, Inc</td>
    </tr>
    <tr>
      <td>relating to regenerative cartilage <font color="blue">technology</font>     and our <font color="blue">distribution</font> <font color="blue">agreement with</font> Heraeus relating to <font color="blue">orthopaedic bone</font>     <font color="blue">cement products</font></td>
    </tr>
    <tr>
      <td>The success of these and similar <font color="blue">arrangements</font> is largely     dependent on <font color="blue">technology</font> and other <font color="blue"><font color="blue">intellectual</font> property</font> contributed by our     <font color="blue">strategic partners</font> or the resources, efforts, and skills of these partners</td>
    </tr>
    <tr>
      <td>Disputes and <font color="blue">difficulties</font> in such <font color="blue">relationships</font> are common, often due to     <font color="blue">conflicting</font> priorities or conflicts of interest</td>
    </tr>
    <tr>
      <td>Merger and <font color="blue">acquisition</font>     activity may exacerbate these conflicts</td>
    </tr>
    <tr>
      <td>The benefits of these alliances are     reduced or eliminated when <font color="blue">strategic partners</font>:       •  terminate the <font color="blue">agreements</font> or limit our access to the underlying     <font color="blue"><font color="blue">intellectual</font> property</font>;       •  fail to <font color="blue">devote financial</font> or other resources to the alliances and thereby     hinder or delay <font color="blue">development</font>, <font color="blue">manufacturing</font> or <font color="blue">commercialization</font> <font color="blue">activities</font>;       •   fail  to  <font color="blue">successfully</font>  develop,  <font color="blue">manufacture</font> or <font color="blue">commercialize</font> any     products; or       •  fail to maintain the <font color="blue">financial resources necessary</font> to <font color="blue">continue financing</font>     their portion of the <font color="blue">development</font>, <font color="blue">manufacturing</font>, or <font color="blue"><font color="blue">commercialization</font> costs</font>     or their own <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Furthermore,  under some of our <font color="blue">strategic alliances</font>, we may make     <font color="blue">milestone payments well</font> in advance of <font color="blue">commercialization</font> of <font color="blue">products with no</font>     assurance that we <font color="blue">will ever recoup</font> these payments</td>
    </tr>
    <tr>
      <td>We also may make equity     <font color="blue">investment</font>s in our <font color="blue">strategic partners</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">investment</font>s may decline in     value and result in our <font color="blue">incurring financial statement charges</font> in the future</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> a limited number of suppliers for some <font color="blue">key <font color="blue">raw materials</font></font>     and outsourced <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We use a number of suppliers for <font color="blue">raw materials</font> we need to <font color="blue">manufacture</font>     our products and to outsource some key <font color="blue">manufacturing</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">suppliers must provide</font> the materials and perform the <font color="blue">activities</font> to our     standards for us to                                                                           19       _________________________________________________________________    [73]Table of Contents       ZIMMER HOLDINGS, INC AND SUBSIDIARIES 2005 FORM 10-K         meet our quality and <font color="blue">regulatory</font> requirements</td>
    </tr>
    <tr>
      <td>Some <font color="blue">key <font color="blue">raw materials</font></font> and     outsourced <font color="blue">activities</font> can only be obtained from a <font color="blue">single source</font> or a limited     number of sources</td>
    </tr>
    <tr>
      <td>A <font color="blue">prolonged disruption</font> or other <font color="blue">inability</font> to obtain these     materials or <font color="blue">activities</font> could <font color="blue">materially</font> and <font color="blue">adversely</font> affect our ability to     <font color="blue">satisfy demand</font> for our products, <font color="blue">which could</font> have a material adverse effect     on our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our future <font color="blue">profitability</font> may be <font color="blue">affected by</font> changes to our product     category and <font color="blue">region sales mix</font></td>
    </tr>
    <tr>
      <td><font color="blue">Reconstructive </font>implants produce the highest operating <font color="blue">profit margins</font>     among our <font color="blue">product categories</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">products accounted</font> for <font color="blue">approximately</font>     83 percent of 2005 net sales</td>
    </tr>
    <tr>
      <td>Sales in our <font color="blue">Americas </font><font color="blue">region accounted</font> for     <font color="blue">approximately</font> 59 percent of 2005 net sales</td>
    </tr>
    <tr>
      <td>Sales in the <font color="blue">Americas </font>region     produce the highest operating <font color="blue">profit margins</font> in the <font color="blue">geographic markets</font> in     which we operate</td>
    </tr>
    <tr>
      <td>While we expect net sales of <font color="blue">reconstructive</font> implants and     net sales in the <font color="blue">Americas </font>region to <font color="blue">remain strong</font>, changes to our product     category mix or our <font color="blue">region sales mix</font> could <font color="blue">adversely</font> affect our future     <font color="blue">profitability</font></td>
    </tr>
  </tbody>
</table>